Kymera Therapeutics (KYMR) Receivables - Other (2020 - 2025)

Kymera Therapeutics (KYMR) has 6 years of Receivables - Other data on file, last reported at $20.0 million in Q1 2025.

• Receivables - Other for Q1 2025 came in at $20.0 million, up 885.22% year-over-year; the trailing twelve-month figure through Mar 2025 was $20.0 million (up 885.22% YoY), and the FY2024 annual result was $900000.0, down 76.08% from the prior year.
• Receivables - Other grew to $20.0 million in Q1 2025 per KYMR's latest filing, from $900000.0 in the prior quarter.
• Over five years, Receivables - Other peaked at $20.0 million in Q1 2025 and troughed at $100000.0 in Q4 2021.
• A 5-year average of $3.3 million and a median of $2.0 million in 2024 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2021 and 2022: Receivables - Other slumped 88.89% in 2021, then soared 2400.0% in 2022.
• A 5-year view of Receivables - Other shows it stood at $100000.0 in 2021, then soared by 2400.0% to $2.5 million in 2022, then soared by 50.48% to $3.8 million in 2023, then slumped by 76.08% to $900000.0 in 2024, then surged by 2122.22% to $20.0 million in 2025.
• Business Quant data shows KYMR's Receivables - Other at $20.0 million in Q1 2025, $900000.0 in Q4 2024, and $1.3 million in Q3 2024.